Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RNA | PRESS-RELEASE | neutral | 4/10 | Atrium Therapeutics reported Q2 2026 collaboration revenue of $3.0M, a net loss of -$1.18 per share, and highlighted FDA | Aug 13, 2026 |
| AKTX | 8-K | neutral | 5/10 | Akari Therapeutics reported Q2 2026 financial results, highlighting a net loss of $4.8M (vs. $1.9M in Q2 2025) as R&D ex | Aug 13, 2026 |
| CLDI | 8-K | mixed | 6/10 | Calidi Biotherapeutics reported Q2 2026 results with a net loss of $4.2M ($2.94/share), narrowing from $5.7M ($31.75/sha | Aug 13, 2026 |
| RNA | 8-K | neutral | 5/10 | Atrium Therapeutics reported Q2 2026 collaboration revenue of $3.0M, down 22% YoY from $3.8M, and a net loss of -$20.2M | Aug 13, 2026 |
| ASMB | PRESS-RELEASE | bullish | 6/10 | Assembly Biosciences reported Q2 2026 EPS of -$0.20, beating consensus of -$0.53 by 62.3%, and collaboration revenue of | Aug 13, 2026 |
| KOD | PRESS-RELEASE | neutral | 6/10 | Kodiak Sciences reported Q2 2026 net loss of $65.6M ($1.05/share), wider than the $54.3M loss in Q2 2025, with R&D spend | Aug 13, 2026 |
| KOD | 8-K | neutral | 4/10 | Kodiak Sciences reported Q2 2026 financial results with a net loss of $65.6M ($1.05/share), wider than the $54.3M loss i | Aug 13, 2026 |
| EVO | 6-K | bearish | 7/10 | Evotec SE reported H1 2026 results showing a sharp decline in financial performance, with Group revenues falling 19.2% Y | Aug 13, 2026 |
| ANNX | ANALYST-UPGRADE | bullish | 4/10 | Citizens double-upgraded Annexon (ANNX) to Market Perform from Market Underperform on August 13, 2026, without setting a | Aug 13, 2026 |
| PHAR | 6-K | bullish | 6/10 | Pharming announced the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4+, following NHI drug p | Aug 13, 2026 |
| RDY | 6-K | neutral | 3/10 | Dr. Reddy's Laboratories filed a 6-K disclosing the resignation of Mr. Deepak Sapra, CEO of API and Services and Senior | Aug 13, 2026 |
| SLXN | 424B4 | bearish | 7/10 | Silexion Therapeutics priced a dilutive best-efforts offering of 2,028,619 ordinary shares and 1,817,542 pre-funded warr | Aug 13, 2026 |
| KRRO | CLUSTER | neutral | 4/10 | Korro Bio's CEO sold $63K worth of shares while a 10% owner bought $60K, creating a mixed insider cluster. The CEO sale | Aug 13, 2026 |
| BFRI | 8-K | bullish | 7/10 | Biofrontera reported Q2 2026 net product revenue of $12.0M (+32.9% YoY), a net loss of $0.6M ($-0.05/share) vs a $5.3M l | Aug 13, 2026 |
| FTLF | 8-K | mixed | 5/10 | FitLife Brands reported Q2 2026 revenue of $26.5M (+65% YoY, driven by the Irwin Naturals acquisition) and diluted EPS o | Aug 13, 2026 |
| FATE | 8-K | neutral | 5/10 | Fate Therapeutics reported Q2 2026 results with a net loss of $0.25 per share, slightly beating the consensus estimate o | Aug 13, 2026 |
| PDSB | 8-K | bearish | 7/10 | PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensus of -$0.13, and announced a strategic refocus to pr | Aug 13, 2026 |
| CING | 8-K | neutral | 4/10 | Cingulate reported Q2 2026 financial results with a net loss of $5.9M, widening from $5.0M a year ago, as SG&A expenses | Aug 13, 2026 |
| DWTX | 8-K | bearish | 6/10 | Dogwood Therapeutics reported Q2 2026 net loss of $11.5M ($0.34/share) vs $3.8M ($1.99/share) in Q2 2025, driven by a $9 | Aug 13, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber published a whitepaper detailing its patent-pending Quantum Photonic Antenna architecture, an early-stage | Aug 13, 2026 |
| EPRX | 6-K | bullish | 6/10 | Eupraxia Pharmaceuticals reported positive symptom response data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI | Aug 13, 2026 |
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma reported a transformative Q2 2026 with revenue surging to EUR 339.3M (up 115% YoY) driven by YORVIPATH g | Aug 13, 2026 |
| RADX | 6-K | bearish | 7/10 | Radiopharm Theranostics filed a 6-K furnishing a notice of an Extraordinary General Meeting (EGM) scheduled for Septembe | Aug 13, 2026 |
| CMND | PRESS-RELEASE | bullish | 6/10 | Clearmind Medicine received DSMB approval to advance its Phase I/II trial of CMND-100 for Alcohol Use Disorder to Parts | Aug 13, 2026 |
| RMTI | 8-K | neutral | 2/10 | Rockwell Medical, Inc. filed an 8-K on August 13, 2026, disclosing an updated corporate presentation under Item 7.01 Reg | Aug 13, 2026 |
| COLL | 8-K | bullish | 5/10 | Collegium Pharmaceutical announced an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 | Aug 13, 2026 |
| NGEN | 6-K | neutral | 5/10 | NervGen Pharma reported Q2 2026 financial results, highlighting a net loss of C$29.2M (C$0.32/share basic) vs C$9.1M (C$ | Aug 13, 2026 |
| CADL | 8-K | neutral | 4/10 | Candel Therapeutics reported Q2 2026 financial results with a net loss of $38.9M ($0.52/share), significantly wider than | Aug 13, 2026 |
| PULM | 8-K | neutral | 4/10 | Pulmatrix reported Q2 2026 financial results, showing a net loss of $1.036M ($0.29/share) compared to a $1.549M loss ($0 | Aug 13, 2026 |
| CADL | PRESS-RELEASE | bullish | 7/10 | Candel Therapeutics reported Q2 2026 financial results with a net loss of $38.9M ($0.52 per share), significantly wider | Aug 13, 2026 |